Baloxavir Shows Promise in Reducing Household Transmission of Influenza
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on May 19th, 2025
|
While often regarded as a seasonal inconvenience for healthy adults, influenza can pose a serious, even fatal, threat to children, the elderly, and immunocompromised individuals. Each flu season typically involves the circulation of four distinct influenza strains, all of which are included in the annually updated vaccine. However, because the vaccine formulation relies on predictive modeling of which strains will dominate, its effectiveness varies from year to year and can be suboptimal. Although antivirals for influenza are available, there is limited conclusive evidence supporting their ability to reduce transmission. In pursuit of new options, Roche sponsored a study to evaluate the potential of baloxavir to lower influenza contagiousness.
This phase 3 clinical trial enrolled 1,457 individuals who tested positive for influenza and 2,681 of their household contacts who were not infected. Influenza diagnosis was confirmed via either PCR or antigen testing, and all participants—both index cases and household members—were screened negative for SARS-CoV-2. None of the household contacts had received an influenza vaccine within the preceding six months, although vaccination status of the index cases was not reported. The trial spanned five flu seasons from 2019 to 2024, with data from the 2020–2021 season omitted due to the COVID-19 pandemic.
Index patients were randomly assigned to receive either a single dose of baloxavir (ranging from 40 to 80 mg depending on body weight) or a placebo, while household contacts received no treatment. Baloxavir acts by inhibiting the viral endonuclease enzyme, which influenza viruses use to "cap-snatch" the 5' end of host mRNA. This cap protects host RNA from degradation and facilitates protein synthesis. By blocking this enzymatic activity, baloxavir prevents the virus from hijacking host mRNA caps, thereby suppressing viral replication.
Follow-up of household contacts for five days after symptom onset in the index patient showed that baloxavir reduced the risk of influenza transmission by 29%. This protective effect was consistent across all four major influenza strains, across age groups, and throughout multiple flu seasons. Additional analysis revealed that drug-resistant variants emerged in 7.2% of the baloxavir-treated index cases; however, these resistant strains were not detected among any of the household contacts. Researchers hypothesized that the lack of transmission was likely because resistant strains arose later in the course of infection, after the peak viral load period when most transmission would occur.
This phase 3 clinical trial enrolled 1,457 individuals who tested positive for influenza and 2,681 of their household contacts who were not infected. Influenza diagnosis was confirmed via either PCR or antigen testing, and all participants—both index cases and household members—were screened negative for SARS-CoV-2. None of the household contacts had received an influenza vaccine within the preceding six months, although vaccination status of the index cases was not reported. The trial spanned five flu seasons from 2019 to 2024, with data from the 2020–2021 season omitted due to the COVID-19 pandemic.
Index patients were randomly assigned to receive either a single dose of baloxavir (ranging from 40 to 80 mg depending on body weight) or a placebo, while household contacts received no treatment. Baloxavir acts by inhibiting the viral endonuclease enzyme, which influenza viruses use to "cap-snatch" the 5' end of host mRNA. This cap protects host RNA from degradation and facilitates protein synthesis. By blocking this enzymatic activity, baloxavir prevents the virus from hijacking host mRNA caps, thereby suppressing viral replication.
Follow-up of household contacts for five days after symptom onset in the index patient showed that baloxavir reduced the risk of influenza transmission by 29%. This protective effect was consistent across all four major influenza strains, across age groups, and throughout multiple flu seasons. Additional analysis revealed that drug-resistant variants emerged in 7.2% of the baloxavir-treated index cases; however, these resistant strains were not detected among any of the household contacts. Researchers hypothesized that the lack of transmission was likely because resistant strains arose later in the course of infection, after the peak viral load period when most transmission would occur.